Medical Isotopes Market Report 2026

The medical isotopes market size has grown strongly in recent years. It will grow from $7.26 billion in 2025 to $7.79 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to established use of technetium 99m in diagnostics, expansion of hospital nuclear medicine departments, growth in cancer diagnosis rates, reliance on nuclear reactors for isotope supply, advances in medical imaging equipment.

The medical isotopes market size is expected to see strong growth in the next few years. It will grow to $10.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing prevalence of chronic diseases, rising demand for targeted radiotherapy, investment in cyclotron infrastructure, growth of personalized medicine, technological advancements in isotope production methods. Major trends in the forecast period include rising use of radioisotopes in diagnostic imaging, growing adoption of nuclear medicine therapies, increasing demand for precision oncology treatments, expansion of cyclotron based isotope production, higher focus on short lived isotope supply chains.

The rising cancer and heart disease rates are expected to propel the growth of the medical isotope market going forward. Cancer and heart disease rates refer to how frequently these conditions occur and persist within a population over a given period, reflecting broader public health patterns and the effectiveness of prevention strategies. The increasing prevalence of these diseases is linked to modern sedentary lifestyles driven by technology use and desk-based occupations, which reduce physical activity levels. Medical isotopes play a critical role in diagnosing and treating cancer and heart disease through imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), as well as in therapeutic applications including radiation therapy and radioactive stents. For instance, in August 2024, according to Macmillan Cancer Support, more than 3 million people in the UK were living with cancer, a number projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, rising cancer and heart disease rates are driving the growth of the medical isotope market.

Major companies in the medical isotope market are focusing on strategic collaborations to strengthen their competitive position. Strategic collaborations involve formal partnerships between organizations to pursue shared goals and deliver mutually beneficial outcomes. For example, in September 2023, International Isotopes Inc., a US-based medical technology company, partnered with Phantech Medical, a US-based biomedical hardware manufacturer, to integrate solutions for their customers. Through this collaboration, the companies aim to transform the calibration and reference sources market for pre-clinical imaging by designing, manufacturing, and distributing innovative sealed sources that support medical imaging and theranostics applications.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired ARTMS Inc. for an undisclosed amount. This acquisition provides Telix with enhanced access to ARTMS' cutting-edge radiopharmaceutical production technologies, strengthening its capabilities in developing and commercializing targeted radiopharmaceuticals for cancer imaging and therapy. ARTMS Inc. is a Canada-based medical equipment manufacturer specializing in technologies that improve the production of diagnostic imaging isotopes.

Major companies operating in the medical isotopes market are Rosatom State Atomic Energy Corporation, Bayer AG, Siemens Healthineers AG, GE HealthCare, Urenco Ltd., Lantheus Holdings Inc., Curium Pharma, Canadian Nuclear Laboratories, Eckert & Ziegler Strahlen- und Medizintechnik AG., Advanced Accelerator Applications a Novartis company, Nordion Inc., NTP Radioisotopes SOC Ltd., The Institute for Radioelements (IRE), NorthStar Medical Radioisotopes LLC, Isotopen Technologien München AG (ITM), Eczacıbaşı-Monrol Nuclear Products Co., SHINE Medical Technologies LLC, Blue Earth Diagnostics Limited, Isologic Innovative Radiopharmaceuticals, IBA Radiopharma Solutions, Izotóp, Coquí RadioPharmaceuticals Corp., Jubilant DraxImage Inc.

North America was the largest region in the medical isotopes market in 2025. The regions covered in the medical isotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical isotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The medical isotopes market consists of sales of technetium-99m, carbon-11, and gallium-68 which serve specific purposes in medical diagnosis and therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.